As MOG antibody positive patients have distinct clinical features (being young, less frequent area postrema syndrome, typically presenting ADEM initially, lower disability during follow-up, a longer time interval till the first relapse), the authors regard MOG antibody-associated disorder as a new phenotype, discriminating it in terms of its diagnostic algorithm from MS, AQP-4 antibody positive NMOSD, and antibody-negative recurrent demyelinating syndrome (83). This evidence concerns the gene AQP4 and acute disseminated encephalomyelitis.